Search
Veracyte Inc
VCYTAdd to Watchlist
57.080USD
-2.770-4.63%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.53BMarket Cap
51.19P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.63%
5 Days
-5.64%
1 Month
+17.23%
6 Months
+34.65%
Year to Date
+35.58%
1 Year
+107.49%
Key Figures
59.920Open
60.584High
1.15MVolume
51.19P/E TTM
47.03P/E Dynamic
--Dividend TTM
1.45%Turnover Ratio
59.850Prev. Close
56.500Low
52.06MTurnover
187.66P/E Static
3.46P/B
0.00%Div Yield TTM
6.40%ROA
50.71052wk High
1.14Volume Ratio
24.14MNet Profit
79.36MShares
1.1150EPS TTM
1.98Beta
6.93%ROE
22.61052wk Low
6.82%Amplitude
72.32%Gross Margin
4.53BMarket Cap
7.21Reward/Risk
2.75%Risk Rate
TradingKey Stock Score of Veracyte Inc
Currency: USD Updated: 2026-07-02Key Insights
Veracyte Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.18.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Veracyte Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Veracyte Inc Highlights
StrengthsRisks
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 43.23% year-on-year.
Fairly Valued
The company’s latest PE is 51.19, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 96.10M shares, decreasing 1.93% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.21M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.50.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
52.545
Target Price
-12.20%
Upside Space
Veracyte Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Veracyte Inc Info
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Ticker SymbolVCYT
CompanyVeracyte Inc
CEOStapley (Marc A)
Websitehttps://www.veracyte.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Veracyte Inc (VCYT)?
The current price of Veracyte Inc (VCYT) is 57.08.
What is the symbol of Veracyte Inc?
The ticker symbol of Veracyte Inc is VCYT.
What is the 52-week high of Veracyte Inc?
The 52-week high of Veracyte Inc is 50.71.
What is the 52-week low of Veracyte Inc?
The 52-week low of Veracyte Inc is 22.61.
What is the market capitalization of Veracyte Inc?
The market capitalization of Veracyte Inc is 4.53B.
Is Veracyte Inc (VCYT) currently rated as Buy, Hold, or Sell?
According to analysts, Veracyte Inc (VCYT) has an overall rating of Buy, with a price target of 52.55.
What is the Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT)?
The Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT) is 0.84.